TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on January 20, 2015. The report addresses the entry into a material definitive agreement and the subsequent filing of a redacted version of that agreement following comments from the Securities and Exchange Commission (SEC).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement and does not contain financial statement data.
Material Changes
The primary material event is the filing of a revised Licensing Agreement dated September 22, 2014, between TG Therapeutics, Inc. and Rhizen Pharmaceuticals S.A. The Company received comments from the SEC on its Confidential Treatment Application regarding this agreement on December 15, 2014. Following verbal comments and negotiations, the Company revised both the application and the agreement. The newly redacted agreement is filed as Exhibit 10.1.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or specific risk factors beyond the standard disclosure that confidential portions of the Licensing Agreement have been redacted and separately filed with the Commission. No unusual items or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Verify the terms of the Licensing Agreement with Rhizen Pharmaceuticals S.A. by reviewing the redacted Exhibit 10.1 filed with this report.
- Confirm the status of the Confidential Treatment Application and the specific portions of the agreement that were redacted.
- Review the original agreement date (September 22, 2014) to understand the timeline of the partnership relative to the filing date.